{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:21:57Z","timestamp":1769602917130,"version":"3.49.0"},"reference-count":85,"publisher":"CSIRO Publishing","issue":"5","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":2264,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,13]]},"abstract":"<jats:p>This review presents the evidence for azithromycin in the treatment of gonorrhoea, both as monotherapy and as a component of dual therapy. Uncertainties are explored regarding the efficacy of a dual treatment strategy, combining ceftriaxone and azithromycin, in the context of resistance trends and extra-genital infections. The association between microbiological testing and clinical outcome for the individual patient, and the effect of azithromycin use on other sexually transmissible infections, are considered. Finally, in the absence of imminent new antimicrobials, optimising the dose of azithromycin while maintaining tolerability is discussed.<\/jats:p>","DOI":"10.1071\/sh19016","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T19:01:28Z","timestamp":1560798088000},"page":"442-448","source":"Crossref","is-referenced-by-count":11,"title":["Should we still use azithromycin for gonorrhoea treatment?"],"prefix":"10.1071","volume":"16","author":[{"given":"Sarah","family":"Mensforth","sequence":"first","affiliation":[{"name":"ADepartment of Sexual Health and HIV, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, B15 2GW, UK."},{"name":"BCorresponding author. Email: sarahmensforth@nhs.net"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D. C.","family":"Ross","sequence":"additional","affiliation":[{"name":"ADepartment of Sexual Health and HIV, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, B15 2GW, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"issue":"1","key":"2025102617162936400_R1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12879-015-1029-2","article-title":"Current and future antimicrobial treatment of gonorrhoea \u2013 the rapidly evolving Neisseria gonorrhoeae continues to challenge.","volume":"15","author":"Unemo","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025102617162936400_R2","unstructured":"Public Health England. Gonococcal resistance to antimicrobials surveillance programme report. Data on trends in antimicrobial resistance and decreased susceptibility in gonococcal infection in England and Wales provided by GRASP. London: PHE Publications; 2018. Available online at: https:\/\/www.gov.uk\/government\/publications\/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-report [verified 19 January 2019]."},{"key":"2025102617162936400_R3","unstructured":"European Centre for Disease Prevention and Control. European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP). Sweden: ECDC; 2019. Available online at: https:\/\/ecdc.europa.eu\/en\/about-us\/partnerships-and-networks\/disease-and-laboratory-networks\/euro-gasp [verified 19 January 2019]."},{"key":"2025102617162936400_R4","unstructured":"Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project (GISP). Atlanta: CDC; 2015. Available online at: https:\/\/www.cdc.gov\/std\/gisp\/default.htm [verified 17 December 2018]."},{"key":"2025102617162936400_R5","unstructured":"World Health Organization. The Gonococcal Antimicrobial Surveillance Programme (GASP). Geneva: WHO; 2019. Available online at: https:\/\/www.who.int\/reproductivehealth\/topics\/rtis\/gonococcal_resistance\/en [verified 19 January 2019]."},{"key":"2025102617162936400_R6","unstructured":"Australian Government Department of Health. Gonorrhoea Surveillance 2018. Canberra: Commonwealth of Australia; 2018. Available online at: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-gonorrhoea-surveil.htm [verified 19 January 2019]."},{"issue":"27","key":"2025102617162936400_R7","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018.","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"key":"2025102617162936400_R8","unstructured":"Australian Government Department of Health. Gonorrhoea health alert, multi-drug resistant gonorrhoea. Canberra: Commonwealth of Australia; 2018. Available online at: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-gonorrhoea.htm [verified 15 October 2018]."},{"key":"2025102617162936400_R9","unstructured":"Electronic Medicines Compendium. Azithromycin 500mg tablets summary of product characteristics [summary of product characteristics]. Surrey: Datapharm Communications Limited; 2018. Available online at: https:\/\/www.medicines.org.uk\/emc\/product\/6541\/smpc [verified 10 December 2018]."},{"issue":"5","key":"2025102617162936400_R10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177615","article-title":"Measurement of tissue azithromycin levels in self-collected vaginal swabs post treatment using liquid chromatography and tandem mass spectrometry (LC-MS\/MS).","volume":"12","author":"Vodstrcil","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"2025102617162936400_R11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174372","article-title":"Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men.","volume":"12","author":"Kong","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"2025102617162936400_R12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/jac\/dky548","article-title":"Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review.","volume":"74","author":"Kong","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025102617162936400_R13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/37.suppl_C.1","article-title":"Azithromycin\u2014review of key chemical, pharmacokinetic and microbiological features.","volume":"37","author":"Lode","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2025102617162936400_R14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1128\/AAC.00852-06","article-title":"Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen.","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025102617162936400_R15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/31.suppl_E.39","article-title":"Selection of dose regimens of azithromycin.","volume":"31","author":"Foulds","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2025102617162936400_R16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00044011-199816020-00009","article-title":"A phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500 mg once daily for 3 days.","volume":"16","author":"Crokaert","year":"1998","journal-title":"Clin Drug Investig"},{"issue":"4","key":"2025102617162936400_R17","first-page":"244","article-title":"Azithromycin levels in cervical mucus and plasma after a single 1.0 g oral dose for chlamydial cervicitis.","volume":"71","author":"Worm","year":"1995","journal-title":"Genitourin Med"},{"key":"2025102617162936400_R18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues.","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2025102617162936400_R19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/sti.2010.044586","article-title":"Azithromycin in the treatment of infection with Neisseria gonorrhoeae.","volume":"86","author":"Bignell","year":"2010","journal-title":"Sex Transm Infect"},{"issue":"8","key":"2025102617162936400_R20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/cid\/ciu521","article-title":"The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.","volume":"59","author":"Kirkcaldy","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2025102617162936400_R21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00007435-199403000-00010","article-title":"Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea.","volume":"21","author":"Handsfield","year":"1994","journal-title":"Sex Transm Dis"},{"issue":"11","key":"2025102617162936400_R22","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/jac\/dku221","article-title":"A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis.","volume":"69","author":"Yasuda","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025102617162936400_R23","doi-asserted-by":"publisher","first-page":"A3","DOI":"10.1136\/sextrans-2016-052718.6","article-title":"O006 Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?","volume":"92","author":"Dean","year":"2016","journal-title":"Sex Trans Infect"},{"issue":"8","key":"2025102617162936400_R24","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/00007435-200208000-00010","article-title":"A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis.","volume":"29","author":"Hook","year":"2002","journal-title":"Sex Transm Dis"},{"issue":"2","key":"2025102617162936400_R25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/antibiotics3020109","article-title":"Clinical efficacy of a single two gram dose of azithromycin extended release for male patients with urethritis.","volume":"3","author":"Takahashi","year":"2014","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"2025102617162936400_R26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002499","article-title":"Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: a retrospective study of national surveillance data from 2013 to 2016.","volume":"15","author":"Yin","year":"2018","journal-title":"PLoS Med"},{"issue":"1","key":"2025102617162936400_R27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3201\/eid2201.151247","article-title":"Decline in decreased cephalosporin susceptibility and increase in azithromycin resistance in Neisseria gonorrhoeae, Canada.","volume":"22","author":"Martin","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"2025102617162936400_R28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/OLQ.0b013e31827bd64c","article-title":"Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011.","volume":"40","author":"Hottes","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"1","key":"2025102617162936400_R29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12879-017-2707-z","article-title":"Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24 European countries, 2015.","volume":"17","author":"Cole","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2025102617162936400_R30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/jac\/dkn235","article-title":"Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland.","volume":"62","author":"Palmer","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2025102617162936400_R31","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/cid\/cix898","article-title":"Increases in Neisseria gonorrhoeae with reduced susceptibility to azithromycin among men who have sex with men in Seattle, King County, Washington, 2012\u20132016.","volume":"66","author":"Barbee","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025102617162936400_R32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1473-3099(18)30122-1","article-title":"Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study.","volume":"18","author":"Fifer","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025102617162936400_R33","unstructured":"Public Health England. Surveillance of antimicrobial resistance in Neisseria gonorrhoeae in England and Wales. Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP). London: PHE Publications; 2018. Available online at: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/746261\/GRASP_2017_report.pdf [verified 17 December 2018]."},{"issue":"12","key":"2025102617162936400_R34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/OLQ.0b013e3181b61bb1","article-title":"Emergence of high level azithromycin-resistant Neisseria gonorrhoeae strain isolated in Argentina.","volume":"36","author":"Galarza","year":"2009","journal-title":"Sex Transm Dis"},{"issue":"6","key":"2025102617162936400_R35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/cid\/cir929","article-title":"Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States.","volume":"54","author":"Katz","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025102617162936400_R36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/OLQ.0000000000000265","article-title":"Failure of azithromycin 2.0 g in the treatment of gonococcal urethritis caused by high-level resistance in California.","volume":"42","author":"Gose","year":"2015","journal-title":"Sex Transm Dis"},{"issue":"12","key":"2025102617162936400_R37","first-page":"3404","article-title":"Occurrence of high-level azithromycin-resistant Neisseria gonorrhoeae isolates in China.","volume":"70","author":"Xue","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2025102617162936400_R38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jac\/dkp188","article-title":"Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales.","volume":"64","author":"Chisholm","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2025102617162936400_R39","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1093\/jac\/dkv106","article-title":"Detailed characterization of the first high-level azithromycin-resistant Neisseria gonorrhoeae cases in Ireland.","volume":"70","author":"Lynagh","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2025102617162936400_R40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1128\/AAC.02093-13","article-title":"First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea?","volume":"58","author":"Unemo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2025102617162936400_R41","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dku490","article-title":"Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Australia.","volume":"70","author":"Stevens","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2025102617162936400_R42","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/cid\/cix485","article-title":"Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016.","volume":"65","author":"Katz","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025102617162936400_R43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/sextrans-2015-052312","article-title":"An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England.","volume":"92","author":"Chisholm","year":"2016","journal-title":"Sex Transm Infect"},{"issue":"2","key":"2025102617162936400_R44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jac\/dky438","article-title":"Neisseria gonorrhoeae 23S rRNA A2059G mutation is the only determinant necessary for high-level azithromycin resistance and improves in vivo biological fitness.","volume":"74","author":"Zhang","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025102617162936400_R45","unstructured":"Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. British Association for Sexual Health and HIV national guideline for the management of infection with Neisseria gonorrhoeae (2019) [UK national Guideline]. Macclesfield: BASHH; 2019. Available online at: https:\/\/www.bashhguidelines.org\/media\/1208\/gc-2019.pdf [verified 28 January 2019]."},{"issue":"2","key":"2025102617162936400_R46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0956462412472837","article-title":"2012 European guideline on the diagnosis and treatment of gonorrhoea in adults.","volume":"24","author":"Bignell","year":"2013","journal-title":"Int J STD AIDS"},{"key":"2025102617162936400_R47","unstructured":"Australian STI Management Guidelines. Gonorrhoea. Sydney: ASHA; 2018. Available online at: http:\/\/www.sti.guidelines.org.au\/sexually-transmissible-infections\/gonorrhoea [verified 17 December 2018]."},{"key":"2025102617162936400_R48","unstructured":"Centers for Disease Control and Prevention. Gonococcal infections in adolescents and adults. Atlanta: CDC; 2015. Available online at: https:\/\/www.cdc.gov\/std\/tg2015\/gonorrhea.htm [verified 17 December 2018]."},{"key":"2025102617162936400_R49","unstructured":"World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. Geneva: WHO; 2016. Available online at: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246114\/9789241549691-eng.pdf;jsessionid=5ED7D8422AEFA59D6A3169875E08671A?sequence=1 [verified 17 December 2018]."},{"key":"2025102617162936400_R50","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","article-title":"Drugs of choice for the treatment of uncomplicated gonococcal infections.","volume":"20","author":"Moran","year":"1995","journal-title":"Clinical Infectious Diseases"},{"key":"2025102617162936400_R51","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32817-4","article-title":"Gentamicin compared with Ceftriaxone for the treatment of gonorrhoea: a randomised trial (G-ToG Trial).","author":"Ross","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"2025102617162936400_R52","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/0255-0857.37338","article-title":"Correlation between in vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: a prospective study.","volume":"25","author":"Khaki","year":"2007","journal-title":"Indian J Med Microbiol"},{"issue":"10","key":"2025102617162936400_R53","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00007435-199811000-00002","article-title":"Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters.","volume":"25","author":"Tapsall","year":"1998","journal-title":"Sex Transm Dis"},{"issue":"1","key":"2025102617162936400_R54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00007435-199501000-00007","article-title":"Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?","volume":"22","author":"Moran","year":"1995","journal-title":"Sex Transm Dis"},{"issue":"8","key":"2025102617162936400_R55","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/OLQ.0000000000000312","article-title":"Comparison of antimicrobial susceptibility of urogenital Neisseria gonorrhoeae isolates obtained from women and men.","volume":"42","author":"Kidd","year":"2015","journal-title":"Sex Transm Dis"},{"issue":"3","key":"2025102617162936400_R56","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables.","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2025102617162936400_R57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10156-006-0445-Z","article-title":"In vitro synergistic effects of double combinations of \u03b2-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae.","volume":"12","author":"Furuya","year":"2006","journal-title":"J Infect Chemother"},{"issue":"10","key":"2025102617162936400_R58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1258\/ijsa.2011.011267","article-title":"UK national guideline for the management of gonorrhoea in adults, 2011.","volume":"22","author":"Bignell","year":"2011","journal-title":"Int J STD AIDS"},{"issue":"3","key":"2025102617162936400_R59","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/jac\/dks449","article-title":"Combination therapy for gonorrhoea: in vitro synergy testing.","volume":"68","author":"Pereira","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2025102617162936400_R60","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ijantimicag.2014.10.020","article-title":"Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution.","volume":"45","author":"Wind","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"2025102617162936400_R61","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/jac\/dkt540","article-title":"In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae.","volume":"69","author":"Barbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2025102617162936400_R62","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bjm.2017.06.001","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and epidemiological aspects of an emerging global threat.","volume":"48","author":"Costa-Louren\u00e7o","year":"2017","journal-title":"Braz J Microbiol"},{"issue":"6","key":"2025102617162936400_R63","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1128\/AAC.00038-14","article-title":"Importance of multi-drug efflux pumps in the antimicrobial resistance property of clinical multi-drug resistant isolates of Neisseria gonorrhoeae.","volume":"58","author":"Golparian","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2025102617162936400_R64","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first high-level ceftriaxone resistant strain.","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"8","key":"2025102617162936400_R65","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/jac\/dks162","article-title":"Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain.","volume":"67","author":"C\u00e1mara","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"19","key":"2025102617162936400_R66","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1056\/NEJMc1408109","article-title":"A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia.","volume":"371","author":"Lahra","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2025102617162936400_R67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3201\/eid2402.171756","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017.","volume":"24","author":"Lefebvre","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"2025102617162936400_R68","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","article-title":"High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.","volume":"56","author":"Unemo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"21","key":"2025102617162936400_R69","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.21.1800264","article-title":"Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017.","volume":"23","author":"Poncin","year":"2018","journal-title":"Euro Surveill"},{"issue":"42","key":"2025102617162936400_R70","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.42.17-00659","article-title":"Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017.","volume":"22","author":"Terkelsen","year":"2017","journal-title":"Euro Surveill"},{"issue":"5","key":"2025102617162936400_R71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1258\/0956462971920127","article-title":"Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin.","volume":"8","author":"Young","year":"1997","journal-title":"Int J STD AIDS"},{"issue":"11","key":"2025102617162936400_R72","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/OLQ.0b013e3182685d2b","article-title":"Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011).","volume":"39","author":"Soge","year":"2012","journal-title":"Sex Transm Dis"},{"issue":"14","key":"2025102617162936400_R73","doi-asserted-by":"crossref","DOI":"10.2807\/ese.16.14.19833-en","article-title":"Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010.","volume":"16","author":"Ison","year":"2011","journal-title":"Euro Surveill"},{"issue":"1","key":"2025102617162936400_R74","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/cid\/cix249","article-title":"Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin.","volume":"65","author":"Wind","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025102617162936400_R75","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/sextrans-2017-053461","article-title":"Is previous azithromycin treatment associated with azithromycin resistance in Neisseria gonorrhoeae? A cross-sectional study using national surveillance data in England.","volume":"94","author":"Clifton","year":"2018","journal-title":"Sex Transm Infect"},{"issue":"15","key":"2025102617162936400_R76","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1056\/NEJMc1212055","article-title":"US outpatient antibiotic prescribing, 2010.","volume":"368","author":"Hicks","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2025102617162936400_R77","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/infdis\/jiy551","article-title":"Azithromycin susceptibility among Neisseria gonorrhoeae isolates and seasonal macrolide use.","volume":"219","author":"Olesen","year":"2019","journal-title":"J Infect Dis"},{"issue":"9","key":"2025102617162936400_R78","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/cid\/civ644","article-title":"The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis.","volume":"61","author":"Lau","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025102617162936400_R79","first-page":"147","article-title":"Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations.","volume":"8","author":"Couldwell","year":"2015","journal-title":"Infect Drug Resist"},{"key":"2025102617162936400_R80","doi-asserted-by":"publisher","first-page":"18203","DOI":"10.3402\/ijch.v71i0.18203","article-title":"Mycoplasma genitalium presence, resistance and epidemiology in Greenland.","volume":"71","author":"Gesink","year":"2012","journal-title":"Int J Circumpolar Health"},{"issue":"4","key":"2025102617162936400_R81","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/ciy477","article-title":"Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation.","volume":"68","author":"Read","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025102617162936400_R82","unstructured":"BASHH Clinical Effectiveness Group. Update on the treatment of Chlamydia trachomatis (CT) infection. Macclesfield: BASHH; 2018. Available online at: https:\/\/www.bashhguidelines.org\/media\/1191\/update-on-the-treatment-of-chlamydia-trachomatis-infection-final-16-9-18.pdf [verified 17 December 2018]."},{"key":"2025102617162936400_R83","unstructured":"Australian STI Management Guidelines. Chlamydia. Sydney: ASHA; 2018. Available online at: http:\/\/www.sti.guidelines.org.au\/sexually-transmissible-infections\/chlamydia [verified 17 December 2018]."},{"issue":"2","key":"2025102617162936400_R84","article-title":"High frequency of the 23S rRNA A2058G mutation of Treponema pallidum in Shanghai is associated with a current strategy for the treatment of syphilis.","volume":"4","author":"Lu","year":"2015","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"2025102617162936400_R85","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/OLQ.0b013e31826ae7a8","article-title":"Two mutations associated with macrolide resistance in Treponema pallidum: increasing prevalence and correlation with molecular strain type in Seattle, Washington.","volume":"39","author":"Grimes","year":"2012","journal-title":"Sex Transm Dis"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/16\/5\/442\/1255762\/sh19016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/16\/5\/442\/1255762\/sh19016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:16:35Z","timestamp":1761513395000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/16\/5\/442\/185063\/Should-we-still-use-azithromycin-for-gonorrhoea"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9,13]]}},"URL":"https:\/\/doi.org\/10.1071\/sh19016","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]}}}